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ABSTRACT 
Objective: Biological agents are among the medicines with the highest revenue in the world market. Biosimilars are copies of biological products 
introduced into the market to offer clinical efficacy like the originator or reference product at lower prices. This study aimed to verify the 
characteristics and price differences between biological medicines registered and marketed in Brazil until the end of 2019. 
Methods: All records were collected by November 2019 on the website of the National Health Surveillance Agency (Anvisa). The list of the Chamber 
of Regulation of the Medicines Market (CMED) consulted for the price analysis, has an economic classificatory criterion with eight ranges. 
Categorization, according to the date/period of authorization for marketing, was also made. 
Results: At Anvisa site, there are 144 drugs present in 277 products distributed in three regulatory categories: new, biological, and similar. 
Approximately 73% of drugs have been approved in the past five years. Three classes represent 77.9% of all drugs-antineoplastics and 
immunomodulatory agents (38.6%), blood and blood organ forming (20.7%), and alimentary tract and metabolism (18.6%). Of the 178 products 
listed in the CMED, 26 (14.6%) have prices above 10,000 reais. 
Conclusion: The prices of original products, for most of the inputs, are lower than those of biosimilars, reversing the international logic. 
Keywords: Biological products, Drug price, Access to essential medicines, Health technologies 
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INTRODUCTION 
Just over twenty years ago, biological or biopharmaceutical 
medicines revolutionized the treatment of numerous diseases, 
including severe chronic conditions, such as diabetes, autoimmune 
diseases, hematological diseases, and cancer [1, 2]. These agents 
have an intrinsic complexity that relates to differentiated research 
and development (R and D) and manufacturing processes that are 
difficult to execute, as they are dependent on living organisms [3]. 
They are also associated with specific regulatory processes and 
extensive clinical applicability in the treatment of complex diseases 
[4–6]. Although effective, their high R and D and production costs 
limit their access and use, especially in emerging countries, where 
they can pose a threat to the sustainability of health systems [2, 7].  
In this market, biosimilars are not identical copies of the original 
biological medicine, although they do not present a significant 
difference in efficacy and safety [8–10]. The international price 
reduction, which, on average, does not exceed 30% [11–13], can 
ease pressure on the health budget by facilitating patients' access to 
innovative treatments [2].  
Currently, biological agents are the fastest-growing segment in 
spending on medicines [14]. In Brazil, in 2017, the revenue of the 
companies that sold them was R$ 15,409,519,216 or USD 
491,707,322 [15]. As there are almost no data available on the drug 
market in the country, there is unknown about the sales of reference 
and biosimilar products, whether the latter are gaining ground and 
have contributed to reducing treatment costs.  
The impact of a biosimilar policy to increase competition in the 
pharmaceutical market merits assessment because it would make it 
possible to reduce reference prices. Understanding the profile of 
biological medicines registered in Brazil would allow us to estimate 
the evolution of this market and the challenges to be faced, and it 
would raise questions for the development and regulatory 
evaluation of subsequent versions of these products and biosimilars 
[16].  
In this sense, the present study aimed to analyze the characteristics 
and price differences between biological medicines marketed in 
Brazil until the end of 2019, updating and providing new 
information on the maturation of this market in the country.  
MATERIALS AND METHODS 
Resolution RDC n 55° of November 16, 2010, of the National Health 
Surveillance Agency (Anvisa), defines drugs whose molecule with 
known biological activity is already registered in Brazil as non-new 
biological products and those not yet registered in Brazil as new 
biological products. This classification does not follow the use of the 
biological reference and biosimilar terms most commonly used in 
scientific literature and in clinical guidelines, which causes some 
confusion [17]. The non-adoption of the term biosimilar, according 
to Interfama [18], occurs because the regulatory agency does not 
believe that biosimilarity is a precondition for the copy of a 
biological product to be registered. 
In this context, in RDC n °55/2010, there are two regulatory 
channels for the approval and registration of biological medicines. 
One, regardless of the exercise of comparability, is called an 
“individual development path”. In it, copies that have studies of non-
inferiority and that demonstrate, in addition to the therapeutic 
activity, the safety of the medicine can be authorized [17, 18]. 
Organic products (not new) that are approved are enabled by 
submitting a reduced dossier [11], being, in fact, non-biosimilar 
options, as they have not undergone the exercise of comparability. 
The second called the “path of comparability”, corresponds, in 
theory, to the international biosimilar category. This is because 
comparability in terms of quality, efficacy and safety is carried out 
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with registered biological products that have not necessarily passed 
similar tests [17]. 
The sample was limited to biological products registered in Brazil. 
Market availability was analyzed by consulting valid authorization 
records on the Anvisa portal [19], using the filter “biological 
medicines.” For each product, the “reference drugs” field showed its 
approval for comparability, if present, and for individual 
development, if absent, and indicating whether the product is new or 
biological [17]. Information on therapeutic class and indication was 
completed through individual consultation of each product on the 
same website, carried out between 20 and 26 November 2019. 
There was no filter for the initial registration date. 
A first list of 346 products was established. One drug was withdrawn 
for having its registration canceled and another for having expired 
registration, yielding 344 products in the sample. Then, drugs with 
the same active ingredient but registered in another regulatory 
category were included. By individual search in the system, 56 more 
drugs were added, 24 in the new category, 17 in a similar category, 
and 15 without specification. Drug combinations were excluded, as 
were vaccines, serums, allergens and immunoglobulins used for the 
prophylaxis of some diseases (e. g., human hepatitis B 
immunoglobulin). The initial sample with 344 products became 277 
medicines. 
The drugs were analyzed according to different perspectives. The 
classification used the therapeutic class detailed on the Anvisa page, 
and the Anatomical Therapeutical Chemical (ATC) system, where 
medicines are divided into different groups, according to the organ 
or system in which they work and their chemical properties, 
pharmacological and therapeutic [20]. For the price analysis, the 
value of the cheapest presentation of the price lists of the Medicines 
Market Regulation Chamber (CMED) was taken [21]. The standard 
established was the maximum consumer price (PMC), referring to 
the 18% tax on the circulation of goods and the provision of services. 
A classificatory economic criterion was used, where 8 price ranges 
were established-up to 200.00 reais, between 200 and 500.00; 500-
1,000.00; 1,000-3,000.00; 3,000-10,000.00; 10,000-50,000.00; 
50,000-150,000.00 and above 150,000.00 reais. Classification 
according to the date/period authorization for marketing was also 
granted (from 1988 to 1998, between 1999 and 2009, 2010 and 
2014 and 2015 to 2019). 
This study did not require approval from the institutional review 
board or informed consent because it is based on public data and 
does not involve patient records. 
RESULTS 
The sample consisted of 144 drugs present in 277 drugs, distributed 
in the following regulatory categories: 24 new, 221 biologicals, 17 
similar, and 15 with absent classification. Among the biologicals, 13 
(5.9%) noted their reference drugs; that is, they had their 
registration via comparability. Because biological products 
registered by this alternative are similar to biosimilars but do not 
have this denomination in the country, it is only possible to identify 
them by analyzing their dossier or, if they appear in the search on 
Anvisa's webpage, the name of the original medicines with which 
they are comparable. We take the example of etanercept. In Anvisa's 
database, there are three manufacturing companies and three 
products, each classified in a different regulatory category. One is a 
biological manufactured in an official laboratory, another has no 
described category, but it is internationally known as the original 
product, and the third is categorized as biological, informing its 
reference medicine. The latter is similar to a biosimilar (biological 
registered via comparator), and there are 13 other agents like it in 
the database. 
When classified according to the first level of the ATC, five products 
were not classified: nimotuzumab, phosphatidylserine, dialyzable 
polypeptide of leukocyte extract, and two whose active ingredient 
was Saccharomyces cerevisiae. The rest are listed in the table below.
 
 
Fig. 1: Timeline of biological and biosimilar drug authorizations in Brazil 
Source: Author’s elaboration. Legend: A: Absent; B=Biological; N: New; S: Similar 
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Table 1: Number of biological drugs and pharmaceutical presentations registered with Anvisa according to ATC classification, 1988-2019 
 1988-1998 1999-2009 2010-2014 2015-2019 1988-2019 
ATC first level classification D P D P D P D P D P 
Antiinfectives for Systemic Use 0 0 1 6 1 1 3 9 3 16 
Antineoplastic and Immunomodulating Agents  3 3 10 10 12 12 40 55 54 80 
Dermatologicals 0 0 1 1 0 0 2 3 2 4 
Sensory organs  0 0 1 1 0 0 0 0 1 1 
Systemic Hormonal Preparations, excl. sex hormones and insulins  1 1 2 3 1 2 3 5 4 11 
Blood and Blood Forming Organs  5 5 12 29 6 7 22 28 29 69 
Cardiovascular System 0 0 0 0 0 0 2 2 2 2 
Genito Urinary System and Sex Hormones  1 2 1 1 4 4 2 2 6 9 
Musculo-Skeletal System 0 0 3 7 2 2 4 6 5 15 
Nervous System 1 1 0 0 0 0 2 2 3 3 
Respiratory System  0 0 1 1 0 0 3 3 4 4 
Alimentary Tract and Metabolism  2 3 8 14 7 8 18 32 26 57 
Various 0 0 0 0 0 0 1 1 1 1 
Total 13 15 40 73 33 36 102 148 140 272 
Source: Author’s elaboration. Legend: D-Drug; P-Product. 
 
Although there are 140 registered drugs distributed across 272 
products, 72.9% of these have been approved in the last five years. 
Three classes represent 77.9% of all drugs-Antineoplastic and 
Immunomodulatory Agents (38.6%), Blood and blood organ 
formation (20.7%) and Alimentary tract and metabolism (18.6%), 
distributed in 75 or 7% of medicines (29.4%, 25.4%, 21.0%), 
respectively. In turn, anti-infectives for systemic use and drugs used 
in the genitourinary system have the highest drug/medication ratio, 
approximately one to three. 
Of the 277 products in the sample, 56 were authorized in 2019; 35 in 
2018; 30 in 2017; 10 in 2016; 17 in 2015; 11 in 2014; 4 in 2013; 9 in 
2012; 5 in 2011; 7 in 2010; 14 in 2009; 8 in 2008; 4 in 2007; 9 in 
2006 and in 2005; 3 in 2004; 4 in 2003 and in 2002; 8 in 2001; 9 in 
2000; 5 in 1999; and 16 between 1998 and 1988. In fig. 1, which 
represents the timeline, the products are identified by their 
regulatory categories, year by year. 
Table 2: Organizes the regulatory categories next to the ATC 
classification level. 
 
Table 2: Distribution of products according to the first ATC level and Anvisa regulatory category 
ATC first-level classification  Regulatory category  
 Absent Biological New Similar Total 
Antiinfectives for Systemic Use 1 12 1 2 16 
Antineoplastic and Immunomodulating Agents  2 73 4 1 80 
Dermatologicals 1 3 0 0 4 
Sensory organs  0 1 0 0 1 
Systemic Hormonal Preparations, excl. sex hormones and insulins  3 7 0 1 11 
Blood and Blood Forming Organs  5 48 9 7 69 
Cardiovascular System 0 2 0 0 2 
Genito Urinary System and Sex Hormones  0 7 0 2 9 
Musculo-Skeletal System 0 10 3 2 15 
Nervous System 0 3 0 0 3 
Respiratory System  0 4 0 0 4 
Alimentary Tract and Metabolism  3 47 5 2 57 
Various 0 1 0 0 1 
Total 15 218 22 17 272 
Source: Author’s elaboration.  
 
The records of biologicals intensified in the last 5 y of the analysis, 
between 2014 and 2019 (n = 131; 47.3%), and the records of new 
and similar drugs intensified between 1999 and 2009 (n = 14; 5.1% 
n = 10; 3.6%, respectively). 
Among the 148 most recently approved biologicals, in the 2015-2019 
period, 55 (67.6%) were antineoplastic and immunomodulatory agents. 
In this class, authorizations were concentrated on monoclonal antibodies 
(n = 23; 15.5%) and anti-TNF-α and non-anti-TNF-α (n = 10; 6.8%). With 
great application in the treatment of autoimmune diseases, in oncology 
and as markers of diagnostic tests, monoclonal antibodies usually end 
with the suffix “mabe,” from English, monoclonal antibody, or “mABs” 
[11]. All biologicals approved by the comparability route were 
introduced in the last five years, in contrast to new biological products, 
where only 16.7% (3 drugs) were authorized. 
The following table shows the price ranges of medicines in reais, per 
presentation. 
Fifty-one medicines (18.4% of the total) did not have their prices 
recorded on the CMED list [21]. Of these, 44 (86.3%) were biological, 
of which eight were approved through comparability, 3 (5.9%) were 
similar, 2 (3.9%) were new, and 2 (3.9%) did not have their record 
marked. Of the remaining 226 products, 108 (47.8%) had prices in 
reais less than 1,000, 92 (40.7%) had prices between R$ 3,000, and 
10,000 and 26 (11.5%) had prices above R$ 10,000. 
Biological medicines are the most numerous and expensive. Of the 
178 products registered with the CMED, 26 (14.6%) are priced over 
10,000 reais. Five are classified in the ATC with medications from 
the alimentary tract and metabolism, all of them registered since 
2017. The most expensive enzyme (Alpha-Asphotase) indicated for 
hypophosphatasia (HPP) of perinatal/infantile and juvenile-onset 
costs almost 350 thousand reais. It is also worth mentioning the 
price of 130 thousand reais for two other drugs, Alfacerliponase and 
Teduglutida, for the treatment of neuronal ceroid lipofuscinosis type 
2 (CLN2) and short bowel syndrome (SCI), respectively which are 
dependent on parenteral support. Of the products in the price range 
of 10,000 to 50,000 reais, 14 are antineoplastic, monoclonal 
antibodies, and immunosuppressant’s, all registered since 2014. 
The other three categories, new, similar, and absent, have very 
comparable characteristics, and no drugs among them are priced 
above R$ 10,000. For these three categories, only antineoplastic 
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agents have prices ranging between 3,000 and 10,000 reais. Most 
products are in the lowest price range, below 200 reais, 
approximately 40% for those considered new and absent and 29% 
for similar products. 
 
Table 3: Drug prices according to the categories analyzed 
 Regulatory category  
Price (R$) Similar Biological New Absent Total 
0-200 4 35 9 5 53 
200-500 3 18 4 1 26 
500-1000 5 18 3 3 29 
1.000-3.000 1 41 4 1 47 
3.000-10.000 1 40 2 2 45 
10.000-50.000 0 20 0 0 20 
50.000-150.000 0 5 0 0 5 
>150.000 0 1 0 0 1 
NI 3 44 2 2 51 
Total 17 222 24 14 277 
Source: Author’s elaboration. No information=NI 
 
DISCUSSION 
The collected data show numbers and records that are difficult to 
interpret. A first difficulty concerns registering with Anvisa. Although 
RDC n °55/2010 defines only two regulatory categories, new and 
biological, the registered products include a group of similars and 
another group without classification [17, 22]. What further aggravates 
categorization is that for Anvisa itself, organic products are a category 
for which the registration of similar products is not allowed [8, 23] 
although 17 of 277 inputs (6.1%) had this classification. Unfortunately, 
this is not a new problem. When analyzing the new drugs registered in 
Brazil more than a decade ago, Gava and collaborators [23] suggested 
that Anvisa implement better disclosure of practices related to health 
registration. This information, associated with the characteristics of 
registration approval and commercialization itself, provides important 
elements for prescribers, patients, and industry [24].  
Another barrier to registration is the date of the first authorization 
that is the most recent or the revalidation of the registration. For a 
drug whose marketing was approved in 2014 and whose validity is 
five years, the date that appears will be the revalidation date of 
2019., It is necessary to check the expired approvals of the input to 
search the year of the first registration. 
The highest concentration of approvals occurred between 1999 and 
2009, although the definition of new biologicals appeared in 2010, 
together with RDC n °55/2010,. In contrast, of the 222 biologicals 
approved since 1999, more than 65% of authorizations have 
occurred in the past five years. 
Despite the registration problems, perhaps the most important issue 
is assessing the authorization process for biological agents by 
individual development or comparability. Only the latter ensures 
that these drugs can be considered equivalent to the biosimilars on 
the international market. The first route would make products a 
category more like similars on the non-biologic market. Although 
Anvisa considers this instrument an interesting possibility for 
making medicines available, it practically does not exist in the 
international scenario [17].  
The National Administration of Medicines, Food and Medical Technology 
(ANMAT), an Argentine health regulatory agency, published ANMAT 
Regulation No. 7729/2011, where the comparability exercise must be 
carried out so that the drug to be registered demonstrates the quality 
that is very similar to the reference drugs [25]. The National Medicines 
Agency of Chile (ANAMED) developed Technical Norm 170/2014 [26], 
created based on international criteria and recommendations of the 
World Health Organization (WHO), for the submission and evaluation of 
biopharmaceutical dossiers. This regulation provides tools for the 
authorization of biosimilar products to guarantee the same safety and 
efficacy as innovative biological medicines [26]. 
In Colombia, the abbreviated strategy for comparability of Decree 
1782/2014 [27], although it follows this rationality, is not exactly 
equivalent to a classic shortened mechanism. According to the 
Colombian health authority, the National Institute for the Monitoring 
of Medicines and Foods (INVIMA), the use of the name "shortened 
route" has no less stringent connotations in the evaluation or 
acceleration of review time by the agency because a competitor must 
support its registration application using the available information 
on the safety and efficacy of a product, without exposing animals or 
humans to unnecessary experiments. Reduced procedures are used 
at most health agencies to register synthetic generics [28]. Anvisa 
uses this path, following the same arguments [17]. 
Corroborating this view, Gavíria, and collaborators [28] state that 
the two possible routes for registering a biosimilar medicine follow 
international standards: a complete dossier with robust preclinical 
and clinical evidence of safety and efficacy and an abbreviated 
dossier, with a demonstration of similarity to an originating product 
that is sufficient to justify confidence in the sender's safety and 
effectiveness research. According to the authors, the consensus 
approach for the reduced dossier of a biosimilar medicine involves 
rigorous comparison, proceeding through comparative analytical 
and functional characterization for preclinical and clinical tests.  
This position, however, is not unchallenged. Lietzam [29] states that 
the shortened path for the registration of biosimilars adopted in 
Colombia would correspond, in reality, to a third technique since its 
methods are different from those adopted in the international 
market because they are less careful. In Colombia, there would be 
fundamental differences since the succinct comparability procedure 
(“fast track”) would not correspond to any other model of drug 
approval in Europe or the United States. The path of the complete 
dossier and the path of comparability would correspond to the new 
biological and the biosimilar in Europe and the United States. 
The indications for the use of approved biologicals in Brazil are 
concentrated on antineoplastic and immunomodulatory agents (80), 
primarily for mABs (23), blood preparations (69), and metabolism 
(57). Biopharmaceutical approvals are usual for rheumatic diseases, 
cancers, and autoimmune diseases [30]. 
This picture of authorizations in Brazil is similar to that in the rest of 
the world, as long as the route used is not considered. The first mAB 
therapeutic product was commercialized in 1986. Since then, this 
class of biopharmaceutical products has grown significantly. 
According to Harston [31], of the 59 biosimilars approved by the 
EMA, 26 were mABs, that is, 44%. Insulins, blood products, and 
hormones complete the picture of EMA biosimilar approvals.  
Therapies based on biological products consist of therapeutic 
innovations considered a priority and, thus, represent a significant 
therapeutic advance in the face of the already existing options [32]. 
However, the high cost of treatment with these agents is a barrier to 
access, even in the most developed countries [33].  
In Brazil, a biological (which has used either of the two development 
pathways) is not always cheaper than the reference medicine. 
Medicines with prices above R $ 50,000.00 are biologicals approved 
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by individual development and are two to ten times more expensive 
than those accepted by comparability. This situation distorts the 
national market when the international situation is considered. 
Several authors indicate the possibility of reducing prices and costs 
for health systems through the inclusion of biosimilar medicines [2, 
34–36]. While Europe sells biosimilars with discounts of 20% to 
35% concerning the price of reference products [14], in Spain, they 
cost 30% less than the original products, as agreed by Decree [37, 
38]. German social insurance receives discounts of 10% for 
medicines with the same manufacturing process. As a counterpoint 
to what occurs in these nations, we find in Brazil a scenario [14], 
similar to that found in other emerging countries [39]: companies 
producing biosimilars avoid trading in countries with low price 
policies and low refund rates to preserve projected sales prices.  
This work has some limitations, which requires caution when 
interpreting its findings. Recent approvals for registration, non-
commercialization of the product, or even the absence of distributors 
may be behind the absence of a drug in the market, indicated here by 
the absence of price on the CMED list [21]. Price comparisons between 
originals and biosimilars were made to the extent that they coincided 
in presentation, concentration, and formulation. An ideal price analysis 
would control all these characteristics. 
It would be important to have data on the sale and market share of 
these inputs available to researchers from diverse institutions, 
whether in Brazil or abroad. 
The use of official databases with predetermined structure and 
without information gaps that limit evaluations based on the data 
should be considered. In addition to the great amount of information 
that could potentially be generated for health services, the scarcity 
of studies of this nature and the difficulty of analyzing information 
from databases with so many particularities is highlighted. 
CONCLUSION 
The main objective of this study was to map the characteristics and 
prices of biological and biosimilar medicines marketed in Brazil. 
According to Anvisa [15], biological medicines showed the highest 
growth rate in sales between 2015 and 2017, accounting for 22% of 
total sales in the last year. In contrast, it was the class of drugs with 
the lowest number of units sold. 
In this study, there was no trend, but the prices of the original 
products, for most of the inputs, are lower than those of biosimilars. 
In the last five years, biosimilars or biologicals approved employing 
comparability have obtained their registration with Anvisa and 
started to be commercialized in the country, but their impact is still 
unknown. This market seems to follow the movement of generic 
drugs, with an increased supply of products at lower prices that 
have a small effect on the price levels of reference products. It is 
expected that the optimism present in international literature will 
replicate here and that biosimilars will cause a decrease in the prices 
of innovative biologicals. 
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